Multicentre registry analysis of incremental peritoneal dialysis incidence and associations with patient outcomes.


Journal

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis
ISSN: 1718-4304
Titre abrégé: Perit Dial Int
Pays: United States
ID NLM: 8904033

Informations de publication

Date de publication:
09 2023
Historique:
medline: 8 9 2023
pubmed: 7 9 2023
entrez: 7 9 2023
Statut: ppublish

Résumé

Incremental peritoneal dialysis (PD) is increasingly advocated to reduce treatment burden and costs, with potential to better preserve residual kidney function. Global prevalence of incremental PD use is unknown and use in Australia and New Zealand has not been reported. Binational registry analysis including incident adult PD patients in Australia and New Zealand (2007-2017), examining incidence of and outcomes associated with incremental PD (first recorded PD exchange volume <42 L/week (incremental) vs. ≥42 L/week (standard)). Incremental PD use significantly increased from 2.7% of all incident PD in 2007 to 11.1% in 2017 (mean increase 0.84%/year). Duration of incremental PD use was 1 year or less in 67% of cases. Male sex, Aboriginal and Torres Strait Islander (ATSI) or Māori ethnicities, age 45-59 years, medical comorbidities or treatment at a centre with low use of automated PD or icodextrin was associated with lower incidence of incremental PD use. Low body mass index and higher estimated glomerular filtration rate was associated with higher incidence. After accounting for patient and centre variables, commencing PD with an incremental prescription was associated with reduced peritonitis risk (adjusted hazard ratio 0.73, 95% confidence interval (CI) 0.61-0.86).When kidney transplantation and death were considered as competing risks, the association between incremental PD and peritonitis was not significant (sub-hazard ratio [SHR] 0.91, 95%CI 0.71-1.17, Incremental PD use is increasing in Australia and New Zealand and is not associated with patient harm.

Sections du résumé

BACKGROUND
Incremental peritoneal dialysis (PD) is increasingly advocated to reduce treatment burden and costs, with potential to better preserve residual kidney function. Global prevalence of incremental PD use is unknown and use in Australia and New Zealand has not been reported.
METHODS
Binational registry analysis including incident adult PD patients in Australia and New Zealand (2007-2017), examining incidence of and outcomes associated with incremental PD (first recorded PD exchange volume <42 L/week (incremental) vs. ≥42 L/week (standard)).
RESULTS
Incremental PD use significantly increased from 2.7% of all incident PD in 2007 to 11.1% in 2017 (mean increase 0.84%/year). Duration of incremental PD use was 1 year or less in 67% of cases. Male sex, Aboriginal and Torres Strait Islander (ATSI) or Māori ethnicities, age 45-59 years, medical comorbidities or treatment at a centre with low use of automated PD or icodextrin was associated with lower incidence of incremental PD use. Low body mass index and higher estimated glomerular filtration rate was associated with higher incidence. After accounting for patient and centre variables, commencing PD with an incremental prescription was associated with reduced peritonitis risk (adjusted hazard ratio 0.73, 95% confidence interval (CI) 0.61-0.86).When kidney transplantation and death were considered as competing risks, the association between incremental PD and peritonitis was not significant (sub-hazard ratio [SHR] 0.91, 95%CI 0.71-1.17,
CONCLUSIONS
Incremental PD use is increasing in Australia and New Zealand and is not associated with patient harm.

Identifiants

pubmed: 37674306
doi: 10.1177/08968608231195517
doi:

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

383-394

Auteurs

Melissa S Cheetham (MS)

Department of Nephrology, Sunshine Coast University Hospital, Birtinya, Australia.
Faculty of Medicine, The University of Queensland, Brisbane, Australia.

Yeoungjee Cho (Y)

Faculty of Medicine, The University of Queensland, Brisbane, Australia.
Australasian Kidney Trials Network at the University of Queensland, Brisbane, Australia.
Translational Research Institute, Brisbane, Australia.
Department of Nephrology, Princess Alexandra Hospital, Brisbane, Australia.

Rathika Krishnasamy (R)

Department of Nephrology, Sunshine Coast University Hospital, Birtinya, Australia.
Faculty of Medicine, The University of Queensland, Brisbane, Australia.
Australasian Kidney Trials Network at the University of Queensland, Brisbane, Australia.

Elasma Milanzi (E)

Australasian Kidney Trials Network at the University of Queensland, Brisbane, Australia.

Josephine Chow (J)

Clinical Innovation and Business Unit, South Western Sydney Local Health District, Australia.
Faculty of Medicine, University of New South Wales, Sydney, Australia.
Nursing and Midwifery Research Alliance, The Ingham Institute for Applied Medical Research, Australia.
NICM Health Research Institute, Western Sydney University, Australia.

Carmel Hawley (C)

Faculty of Medicine, The University of Queensland, Brisbane, Australia.
Australasian Kidney Trials Network at the University of Queensland, Brisbane, Australia.
Translational Research Institute, Brisbane, Australia.
Department of Nephrology, Princess Alexandra Hospital, Brisbane, Australia.

Jo-Anne Moodie (JA)

Department of Nephrology, Royal Melbourne Hospital, Australia.

Matthew D Jose (MD)

Australia and New Zealand Dialysis and Transplant Registry (ANZDATA), Australia.
Renal Unit, Royal Hobart Hospital, Tasmania, Australia.
School of Medicine, University of Tasmania, Australia.

Robert MacGinley (R)

Department of Renal Medicine, Eastern Health Clinical School, Monash University, Melbourne, Australia.

Thu Nguyen (T)

Department of Renal Medicine, Auckland District Health Board, New Zealand.

Suetonia C Palmer (SC)

Department of Medicine, University of Otago, Christchurch, New Zealand.

Rachael Walker (R)

School of Nursing, Eastern Institute of Technology, Hawke's Bay, New Zealand.

Jeffrey Wong (J)

Department of Nephrology, Liverpool Hospital, South Western Sydney Local Health District, Australia.

Arsh K Jain (AK)

Schulich School of Medicine and Dentistry, Department of Epidemiology and Biostatistics, Western University, London, Canada.

Neil Boudville (N)

Medical School, University of Western Australia, Perth, Australia.
Department of Renal Medicine, Sir Charles Gairdner Hospital, Perth, Australia.

David W Johnson (DW)

Faculty of Medicine, The University of Queensland, Brisbane, Australia.
Australasian Kidney Trials Network at the University of Queensland, Brisbane, Australia.
Translational Research Institute, Brisbane, Australia.
Department of Nephrology, Princess Alexandra Hospital, Brisbane, Australia.

Louis L Huang (LL)

Department of Renal Medicine, Eastern Health Clinical School, Monash University, Melbourne, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH